Similar articles

• Orphanage at the FDA.

  Chen E. Chen E. J Cardiovasc Transl Res. 2012 Oct;5(5):735-6. doi: 10.1007/s12265-010-9242-2. Epub 2010 Nov 16. J Cardiovasc Transl Res. 2012. PMID: 21080134 No abstract available.
• Rare Diseases: Addressing the Challenges in Diagnosis, Drug Approval, and Patient Access.

  Copley-Merriman K. Copley-Merriman K. Value Health. 2018 May;21(5):491-492. doi: 10.1016/j.jval.2018.03.009. Epub 2018 Apr 10. Value Health. 2018. PMID: 29753343 No abstract available.
• Law and research could add up to profitable niche drugs.

  Haefner B. Haefner B. Nature. 2007 Apr 19;446(7138):856. doi: 10.1038/446856b. Nature. 2007. PMID: 17443162 No abstract available.
• Rare diseases, orphan drugs and their regulation: questions and misconceptions.

  Tambuyzer E. Tambuyzer E. Nat Rev Drug Discov. 2010 Dec;9(12):921-9. doi: 10.1038/nrd3275. Epub 2010 Nov 9. Nat Rev Drug Discov. 2010. PMID: 21060315 Review.
• The Food and Drug Administration's Office of Orphan Products Development: incentives, grants, and special designations speed therapies for orphan diseases.

  Haffner ME. Haffner ME. Retina. 2005 Dec;25(8 Suppl):S89-S90. doi: 10.1097/00006982-200512001-00045. Retina. 2005. PMID: 16374359 Review. No abstract available.